Navigation Links
Forest Laboratories, Inc. Reports Fiscal Year 2009 Fourth Quarter Reported EPS of $0.31 Including $0.45 Per Share Charge Related to the Ongoing United States Attorney's Office Investigation
Date:4/21/2009

$898.7 million in the prior fiscal year. Sales of Lexapro (escitalopram oxalate), an SSRI indicated for the initial and maintenance treatment of major depressive disorder in adults and, most recently, adolescents and generalized anxiety disorder in adults were $548.5 million, a decline of 5.0% from the year-ago period. Sales of Namenda(R), an NMDA receptor antagonist for the treatment of moderate and severe Alzheimer's disease, totaled $243.8 million in the quarter, an increase of 7.7% from last year's fourth quarter. Sales of Bystolic(TM), a beta-blocker approved for the treatment of hypertension, launched in late January 2008, were $29.7 million, just under a twofold increase from the quarter a year ago. Contract revenue of $55.2 million declined 8.2%, principally from the Benicar(R) (olmesartan medoxomil) co-promotion income of $50.5 million, which declined 13.2% compared to last year. Per the agreement with Daiichi Sankyo, active co-promotion of Benicar ended in the first quarter of fiscal 2009 and the Company now receives a gradually reducing residual royalty until the end of March 2014. Interest income of $12.7 million decreased from $31.1 million reported in the prior year, due to lower interest rates earned on the Company's short duration portfolio. Other income was essentially unchanged at $0.8 million. Net revenues for the quarter, which includes net sales, contract revenue, interest and other income, were $965.5 million, a decrease of 2.6% from $990.9 million in the prior fiscal year.

Selling, general and administrative expenses during the quarter increased 57.3% to $515.1 million from $327.4 million last year and included a charge of $170.0 million related to the USAO investigation as well as significant expenses associated with the launch of Bystolic and pre-launch spending for Savella(TM), a selective serotonin norepinephrine dual reuptake inhibitor (SNRI) indicated for the management of fibromyalgia that was approved in Januar
'/>"/>

SOURCE Forest Laboratories, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine news :

1. AUDIO from Medialink and Forest Pharmaceuticals: FDA Approves Lexapro for Major Depressive Disorder in Adolescents
2. Forest Laboratories, Inc. and Cypress Bioscience, Inc. Announce Commercial Availability of Savella(TM)
3. AUDIO from Medialink and Forest Pharmaceuticals: FDA Approves Lexapro for Major Depressive Disorder in Adolescents
4. Forest Laboratories, Inc. Announces FDA Approval of Lexapro(R) for the Treatment of Major Depressive Disorder in Adolescents
5. German Federal Patent Court Invalidates Wake Forest NPWT Patents Licensed to KCI
6. Wake Forest Baptist and Rivulet Connect New Operating Rooms with Interactive Video
7. Forest Laboratories, Inc. and Cypress Bioscience, Inc. Announce Revised Timing for Commercial Availability of Savella(TM)
8. Forest Laboratories, Inc. Provides Statement in Response to Complaint Filed by U.S. Government
9. United States Files Complaint Against Forest Laboratories for Allegedly Violating the False Claims Act
10. Old-Growth Forests Dying Off in U.S. West
11. Forest Laboratories, Inc. Reports Q309 Diluted Earnings Per Share of $0.62, Including $0.41 Per Share Charge for New Product Licensing Fees
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2015)... Illinois (PRWEB) April 18, 2015 Heritage ... will begin its Supportive Living Week Celebration on April ... on having a healthy mind, body and soul. , ... in McLeansboro, Illinois, serves older adults of all incomes, ... maintain their independence. , Supportive Living Week is observed ...
(Date:4/17/2015)... California (PRWEB) April 17, 2015 ... Dr. Kevin Sadati of the Gallery of ... Orange County’s top beauty experts. The publication focused ... lift, facial stem cell fat grafting, eyelid surgery, laser ... facial plastic surgery has resulted in thousands ...
(Date:4/17/2015)... 17, 2015 From the day Dr. Todd ... Texas non-profit organization has empowered young people to create meaningful ... bring fresh water and the Gospel to all of ... Between March 17 and 27, students, faculty and staff raised ... with fresh water and the Good News of Jesus. ...
(Date:4/17/2015)... 17, 2015 Enthusiasts of gourmet cuisine and ... April 25, 2015. The event will be held in the ... (201 Monroe Ave NW, Grand Rapids, MI 49503) and will ... Michigan area. Patrons are encouraged to savor the food and ... , This year’s event will feature seven chefs, including:, ...
(Date:4/17/2015)... York, New York (PRWEB) April 17, 2015 ... that allege this class of prescription medications ... a heart attack, stroke or other life-threatening cardiovascular ... underway in U.S. District Court, Northern District of ... by the U.S. Judicial Panel on Multidistrict Litigation ...
Breaking Medicine News(10 mins):Health News:Heritage Woods of McLeansboro Affordable Assisted Living to Celebrate Supportive Living Week 2Health News:Heritage Woods of McLeansboro Affordable Assisted Living to Celebrate Supportive Living Week 3Health News:Orange County Facial Plastic Surgeon Featured in Premier Magazine Focused on Beauty 2Health News:Orange County Facial Plastic Surgeon Featured in Premier Magazine Focused on Beauty 3Health News:The Last Well and Liberty U’s TEN Initiative raises $21,000 to Bring Fresh Water & The Gospel to 7,000 Liberians 2Health News:Children’s Leukemia Foundation of Michigan Presents 3rd Annual CRUSH Grand Rapids 2Health News:Testosterone Treatment Lawsuits Increase, as New Report Indicates Over 200 Federal Cases Filed Since March 2Health News:Testosterone Treatment Lawsuits Increase, as New Report Indicates Over 200 Federal Cases Filed Since March 3Health News:Testosterone Treatment Lawsuits Increase, as New Report Indicates Over 200 Federal Cases Filed Since March 4
... EpiCept Corporation,(Nasdaq and OMX Nordic Exchange: EPCT) ... be presenting at the 2007 BIO InvestorForum on,October ... the Palace Hotel in San,Francisco, California. Mr. Talley ... http://www.newscom.com/cgi-bin/prnh/20020513/NYM112LOGO ) The presentation will be ...
... Healthcare Services, WASHINGTON, Oct. 3 The American ... override,President Bush,s veto of the State Children,s Health Insurance ... bill by a 265-159 margin. This vote margin,is not ... passed the,measure by a 67-29 margin., "Without this ...
... Million Raised to ... Date, CARLSBAD, ... teaming up,with American Airlines this weekend to support Susan G. Komen for the ... the Four Seasons Resort Aviara and the Del Mar Country Club in,Carlsbad, Calif. ...
... 3 VNUS(R) Medical,Technologies, Inc. (Nasdaq: VNUS ), ... treatment of venous reflux disease, today,announced that it presented ... at 10:00 a.m. ET on October 3, 2007, at ... An archive of the VNUS presentation webcast is ...
... Anadys Pharmaceuticals,Inc. (Nasdaq: ANDS ) announced today ... October 10, 2007, at 11:45 a.m. PDT (2:45,p.m. EDT). ... in San,Francisco. Steve Worland, Ph.D., President and Chief ... of Anadys and an update on,its two development-stage product ...
... Web site from Northwood,Health Systems has won three awards ... effort in partnership with the best,Web designers in West ... Web site technology," Northwood President and Chief,Executive Officer Pete ... more than 1,000 accredited,continuing education courses for health care ...
Cached Medicine News:Health News:EpiCept Corporation to Present at the 2007 BIO InvestorForum 2Health News:EpiCept Corporation to Present at the 2007 BIO InvestorForum 3Health News:American Academy of Child and Adolescent Psychiatry Reacts to S-CHIP Veto 2Health News:American Airlines 13th Annual Celebrity Golf and Tennis Weekend Will Raise Funds to Fight Breast Cancer 2Health News:American Airlines 13th Annual Celebrity Golf and Tennis Weekend Will Raise Funds to Fight Breast Cancer 3Health News:Anadys Pharmaceuticals to Present at BIO InvestorForum 2007 2
(Date:4/17/2015)... Apr. 17, 2015 Research and Markets ... of the "Medical Device Outsourcing - Global ... This report analyzes the worldwide markets ... the following Device Categories: Class I, Class II, ... in the report Include - Radiology, Orthopedic, Neurology, ...
(Date:4/17/2015)... , April 17, 2015 ASSESS ... mutation   is a viable alternative to tumour biopsy   ... in all patients with advanced NSCLC   AstraZeneca ... of plasma circulating tumour DNA (ctDNA) testing for epidermal growth ... advanced non-small cell lung cancer (NSCLC) in clinical practice. [ ...
(Date:4/17/2015)... 17, 2015 Research and Markets ( ... "Medical Oxygen Systems - Global Strategic Business Report" ... the worldwide markets for Medical Oxygen Systems in US$ ... Systems, Oxygen Cylinders & Regulators, and Oxygen Conserving Devices. ... Canada , Japan ...
Breaking Medicine Technology:Medical Device Outsourcing (Radiology, Orthopedic, Neurology, Cardiology, and Others) Market 2015 - Global Strategic Business Report 2Medical Device Outsourcing (Radiology, Orthopedic, Neurology, Cardiology, and Others) Market 2015 - Global Strategic Business Report 3"Real World" Data Support Use of Blood Test for EGFR Mutation in Advanced NSCLC 2"Real World" Data Support Use of Blood Test for EGFR Mutation in Advanced NSCLC 3"Real World" Data Support Use of Blood Test for EGFR Mutation in Advanced NSCLC 4Medical Oxygen Systems - 2015 Global Strategic Business Report Featuring Leading Players, Caire, Invacare & Philips Respironics 2
... PHILADELPHIA, Nov. 7, 2011 The Children,s Hospital of ... Grand Challenges Explorations, an initiative created by the Bill ... test unorthodox ideas that address persistent health and development ... of Rheumatology at Children,s Hospital and Professor of Pediatrics ...
... efforts on behalf of the public and private healthcare industry ... today, according to a new book , "Health Industry ... J. Hicks and Christina Mazzola Nicols of Ketchum , ... The book, released this fall from Jones & Bartlett ...
Cached Medicine Technology:The Children's Hospital of Philadelphia Receives Grand Challenges Explorations Funding 2The Children's Hospital of Philadelphia Receives Grand Challenges Explorations Funding 3New Book Highlights Opportunities for Healthcare Industry Communications 2New Book Highlights Opportunities for Healthcare Industry Communications 3New Book Highlights Opportunities for Healthcare Industry Communications 4New Book Highlights Opportunities for Healthcare Industry Communications 5
Liquichek™ Ethanol/Ammonia Control is a liquid product used to monitor ethanol and ammonia test procedures in the clinical laboratory....
Lyphochek Assayed Chemistry Control requires no special diluent and has good reconstituted stability for enzymes and CO2. It is assayed for most major instruments and methodologies....
Lyphochek Benzo/TCA Control Set B is ideal for monitoring HPLC methods for identification and quantitation of benzodiazepines and antidepressant drugs....
Lyphochek Endocrine Control is a human based product designed to monitor plasma catecholamine testing procedures by HPLC. The analytes are spiked at critical concentrations to cover the dynamic range...
Medicine Products: